Disease Detail

ID DOID:60081
Name triple-receptor negative breast cancer
Definition A breast cancer that is characterized by the absence of estrogen, progresterone and Her2 receptors.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer thoracic cancer breast cancer triple-receptor negative breast cancer

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Unknown unknown Apatinib triple-receptor negative breast cancer not applicable detail...
Unknown unknown AMG 900 triple-receptor negative breast cancer not applicable detail...
Unknown unknown Alisertib + Docetaxel triple-receptor negative breast cancer not applicable detail...
Unknown unknown Lucitanib triple-receptor negative breast cancer not applicable detail...
BRCA1 mutant Carboplatin + Veliparib triple-receptor negative breast cancer sensitive detail...
BRCA1 wild-type Carboplatin + Veliparib triple-receptor negative breast cancer no benefit detail...
Unknown unknown Evofosfamide triple-receptor negative breast cancer not applicable detail...
Unknown unknown tirapazamine triple-receptor negative breast cancer not applicable detail...
Unknown unknown SN30000 triple-receptor negative breast cancer not applicable detail...
Unknown unknown PR-104 triple-receptor negative breast cancer not applicable detail...
BRCA1 wild-type Olaparib triple-receptor negative breast cancer sensitive detail...
BRCA1 mutant Olaparib triple-receptor negative breast cancer sensitive detail...
BRCA1 dec exp Cisplatin triple-receptor negative breast cancer sensitive detail...
BRCA1 dec exp Chlorambucil triple-receptor negative breast cancer sensitive detail...
Unknown unknown BMS-906024 triple-receptor negative breast cancer not applicable detail...
Unknown unknown Eribulin triple-receptor negative breast cancer not applicable detail...
NOTCH1 S2449fs PF-03084014 triple-receptor negative breast cancer sensitive detail...
NOTCH1 mutant PF-03084014 triple-receptor negative breast cancer sensitive detail...
Unknown unknown KW-2450 triple-receptor negative breast cancer not applicable detail...
Unknown unknown KW-2450 + Selumetinib triple-receptor negative breast cancer not applicable detail...
PTEN loss AZD8186 triple-receptor negative breast cancer predicted - sensitive detail...
Unknown unknown Senexin B triple-receptor negative breast cancer not applicable detail...
Unknown unknown BAY1217389 + Paclitaxel triple-receptor negative breast cancer not applicable detail...
Unknown unknown BAY1161909 + Paclitaxel triple-receptor negative breast cancer not applicable detail...
Unknown unknown Docetaxel + NTRC 0066-0 triple-receptor negative breast cancer not applicable detail...
NOTCH1 rearrange MRK-003 triple-receptor negative breast cancer sensitive detail...
NOTCH1 rearrange MRK-003 + SCH772984 triple-receptor negative breast cancer no benefit detail...
NOTCH1 wild-type MRK-003 triple-receptor negative breast cancer decreased response detail...
NOTCH1 rearrange MRK-003 + Paclitaxel triple-receptor negative breast cancer sensitive detail...
NOTCH1 wild-type MRK-003 + Paclitaxel triple-receptor negative breast cancer no benefit detail...
PTEN loss AZD6482 + Talazoparib triple-receptor negative breast cancer sensitive detail...
PTEN loss AZD6482 + Niraparib triple-receptor negative breast cancer sensitive detail...
PTEN loss AZD6482 + Olaparib triple-receptor negative breast cancer sensitive detail...
PTEN loss AZD6482 + Rucaparib triple-receptor negative breast cancer sensitive detail...
PTEN loss AZD6482 + Veliparib triple-receptor negative breast cancer sensitive detail...
Unknown unknown TVB-2640 triple-receptor negative breast cancer not applicable detail...
Unknown unknown CCT007093 + Paclitaxel triple-receptor negative breast cancer not applicable detail...
Unknown unknown CCT007093 triple-receptor negative breast cancer no benefit detail...
Unknown unknown Paclitaxel + Plicamycin triple-receptor negative breast cancer not applicable detail...
Unknown unknown LY2109761 + Paclitaxel triple-receptor negative breast cancer not applicable detail...
Unknown unknown SKLB646 triple-receptor negative breast cancer not applicable detail...
PTEN loss RB1 loss Palbociclib + Pictilisib triple-receptor negative breast cancer no benefit detail...
PTEN loss RB1 loss Pictilisib triple-receptor negative breast cancer resistant detail...
PTEN loss RB1 loss Palbociclib triple-receptor negative breast cancer resistant detail...
SRC positive KX2-391 triple-receptor negative breast cancer sensitive detail...
SRC positive KX2-391 + Paclitaxel triple-receptor negative breast cancer sensitive detail...
JAK2 over exp NVP-BSK805 + Paclitaxel triple-receptor negative breast cancer sensitive detail...
JAK2 amp NVP-BSK805 + Paclitaxel triple-receptor negative breast cancer sensitive detail...
JAK2 amp NVP-BSK805 triple-receptor negative breast cancer sensitive detail...
TP53 R280K YW3-56 triple-receptor negative breast cancer sensitive detail...
BRCA1 wild-type BRCA2 wild-type Everolimus + Talazoparib triple-receptor negative breast cancer sensitive detail...
BRCA1 wild-type BRCA2 wild-type KU-0063794 + Talazoparib triple-receptor negative breast cancer sensitive detail...
BRCA1 wild-type BRCA2 wild-type Everolimus + Olaparib triple-receptor negative breast cancer sensitive detail...
BRCA1 wild-type BRCA2 wild-type KU-0063794 + Olaparib triple-receptor negative breast cancer sensitive detail...
MET dec exp Olaparib triple-receptor negative breast cancer sensitive detail...
MET dec exp Veliparib triple-receptor negative breast cancer sensitive detail...
MET dec exp Rucaparib triple-receptor negative breast cancer sensitive detail...
MET over exp Rucaparib triple-receptor negative breast cancer decreased response detail...
MET over exp Crizotinib + Rucaparib triple-receptor negative breast cancer sensitive detail...
MET over exp Foretinib + Rucaparib triple-receptor negative breast cancer sensitive detail...
BRCA1 dec exp MET dec exp Rucaparib triple-receptor negative breast cancer sensitive detail...
BRCA2 dec exp MET dec exp Rucaparib triple-receptor negative breast cancer sensitive detail...
BRCA1 dec exp MET over exp Rucaparib triple-receptor negative breast cancer no benefit detail...
BRCA2 dec exp MET over exp Rucaparib triple-receptor negative breast cancer no benefit detail...
MET over exp Foretinib + Veliparib triple-receptor negative breast cancer sensitive detail...
MET positive Cabozantinib triple-receptor negative breast cancer sensitive detail...
MET negative Cabozantinib triple-receptor negative breast cancer no benefit detail...
BRCA1 inact mut E7449 triple-receptor negative breast cancer predicted - sensitive detail...
Unknown unknown Alisertib + Paclitaxel triple-receptor negative breast cancer not applicable detail...
BRAF mut KRAS mut CDKN2A mut Trametinib triple-receptor negative breast cancer resistant detail...
SRC positive UM-164 triple-receptor negative breast cancer predicted - sensitive detail...
SRC positive BIRB-796 + Dasatinib triple-receptor negative breast cancer sensitive detail...
Unknown unknown Pemetrexed + Sorafenib triple-receptor negative breast cancer not applicable detail...
Unknown unknown YLL545 triple-receptor negative breast cancer not applicable detail...
Unknown unknown Foretinib triple-receptor negative breast cancer not applicable detail...
Unknown unknown Bevacizumab + Capecitabine + Paclitaxel triple-receptor negative breast cancer not applicable detail...
Unknown unknown JQ1 triple-receptor negative breast cancer not applicable detail...
Unknown unknown Birabresib triple-receptor negative breast cancer not applicable detail...
Unknown unknown Docetaxel + JQ1 triple-receptor negative breast cancer not applicable detail...
Unknown unknown JQ1 + Vinorelbine triple-receptor negative breast cancer not applicable detail...
Unknown unknown Cisplatin + JQ1 triple-receptor negative breast cancer not applicable detail...
Unknown unknown Carboplatin + JQ1 triple-receptor negative breast cancer not applicable detail...
Unknown unknown AMG 900 + Ixabepilone triple-receptor negative breast cancer not applicable detail...
Unknown unknown Selumetinib triple-receptor negative breast cancer not applicable detail...
TP53 mutant Carboplatin + Nutlin-3 triple-receptor negative breast cancer predicted - sensitive detail...
Unknown unknown Carboplatin + Docetaxel + Gemcitabine + Itraconazole triple-receptor negative breast cancer not applicable detail...
Unknown unknown BAY 11-7082 + Erlotinib triple-receptor negative breast cancer not applicable detail...
Unknown unknown Adavosertib + Everolimus triple-receptor negative breast cancer not applicable detail...
Unknown unknown YM155 triple-receptor negative breast cancer not applicable detail...
Unknown unknown Bortezomib triple-receptor negative breast cancer not applicable detail...
Unknown unknown Carfilzomib triple-receptor negative breast cancer not applicable detail...
Unknown unknown KP372-1 triple-receptor negative breast cancer not applicable detail...
Unknown unknown Crizotinib + Navitoclax triple-receptor negative breast cancer not applicable detail...
Unknown unknown Cabozantinib + Navitoclax triple-receptor negative breast cancer not applicable detail...
Unknown unknown Navitoclax + Paclitaxel triple-receptor negative breast cancer not applicable detail...
Unknown unknown Nutlin-3 + Paclitaxel triple-receptor negative breast cancer not applicable detail...
Unknown unknown JQ1 + Paclitaxel triple-receptor negative breast cancer not applicable detail...
PTEN loss M2698 triple-receptor negative breast cancer sensitive detail...
PTEN A72fs DHM25 triple-receptor negative breast cancer sensitive detail...
BRAF G464V KRAS G13D DHM25 triple-receptor negative breast cancer sensitive detail...
PTEN V275* DHM25 triple-receptor negative breast cancer sensitive detail...
Unknown unknown BETd-246 + BM-1197 triple-receptor negative breast cancer not applicable detail...
Unknown unknown BETd-246 + Navitoclax triple-receptor negative breast cancer not applicable detail...
Unknown unknown A-1155463 + BETd-246 triple-receptor negative breast cancer not applicable detail...
TP53 mutant Doxorubicin + Seliciclib triple-receptor negative breast cancer predicted - sensitive detail...
Unknown unknown SY-1365 triple-receptor negative breast cancer not applicable detail...
Unknown unknown Niraparib + SY-1365 triple-receptor negative breast cancer not applicable detail...
TP53 mutant GDC-0425 + Gemcitabine triple-receptor negative breast cancer predicted - sensitive detail...
Unknown unknown BPM 31510 triple-receptor negative breast cancer not applicable detail...
Unknown unknown LY3200882 triple-receptor negative breast cancer not applicable detail...
Unknown unknown CFI-402257 triple-receptor negative breast cancer not applicable detail...
Unknown unknown PF-06647263 triple-receptor negative breast cancer conflicting detail...
Unknown unknown Ipatasertib + Paclitaxel triple-receptor negative breast cancer not applicable detail...
PTEN dec exp Ipatasertib + Paclitaxel triple-receptor negative breast cancer predicted - sensitive detail...
AKT1 mutant Ipatasertib + Paclitaxel triple-receptor negative breast cancer predicted - sensitive detail...
PTEN mutant Ipatasertib + Paclitaxel triple-receptor negative breast cancer predicted - sensitive detail...
BRCA1 mutant Talazoparib triple-receptor negative breast cancer decreased response detail...
BRCA2 mutant Talazoparib triple-receptor negative breast cancer decreased response detail...
Unknown unknown ONC201 triple-receptor negative breast cancer not applicable detail...
Unknown unknown Docetaxel + ONC201 triple-receptor negative breast cancer not applicable detail...
Unknown unknown ONC201 + Paclitaxel triple-receptor negative breast cancer not applicable detail...
AKT1 E17K Capivasertib triple-receptor negative breast cancer predicted - sensitive detail...
Unknown unknown ASTX-660 triple-receptor negative breast cancer not applicable detail...
Unknown unknown ASTX-660 + Paclitaxel triple-receptor negative breast cancer not applicable detail...
Unknown unknown G-TPP + Navitoclax triple-receptor negative breast cancer not applicable detail...
Unknown unknown G-TPP + Obatoclax triple-receptor negative breast cancer not applicable detail...
Unknown unknown Cisplatin + Everolimus + Paclitaxel triple-receptor negative breast cancer no benefit detail...
Unknown unknown Carfilzomib + Tinostamustine triple-receptor negative breast cancer not applicable detail...
Unknown unknown Bortezomib + Tinostamustine triple-receptor negative breast cancer not applicable detail...
Unknown unknown Capivasertib + Olaparib triple-receptor negative breast cancer not applicable detail...
BRCA1 wild-type BRCA2 wild-type Cisplatin + VX-970 triple-receptor negative breast cancer predicted - sensitive detail...
Unknown unknown S63845 triple-receptor negative breast cancer not applicable detail...
Unknown unknown Docetaxel + S63845 triple-receptor negative breast cancer not applicable detail...
Unknown unknown Cyclophosphamide + Doxorubicin + Elenagen triple-receptor negative breast cancer not applicable detail...
ERBB2 V697L Neratinib triple-receptor negative breast cancer sensitive detail...
BRCA1 loss FGFR2-DNM3 BGJ398 triple-receptor negative breast cancer predicted - sensitive detail...
BRCA1 loss FGFR2-DNM3 Buparlisib triple-receptor negative breast cancer decreased response detail...
BRCA1 loss FGFR2-DNM3 BGJ398 + Olaparib triple-receptor negative breast cancer sensitive detail...
BRCA1 loss FGFR2-DNM3 BGJ398 + Talazoparib triple-receptor negative breast cancer sensitive detail...
FGFR2-TNS1 BGJ398 triple-receptor negative breast cancer sensitive detail...
FGFR2-TNS1 BGJ398 + Buparlisib triple-receptor negative breast cancer sensitive detail...
FGFR2-TNS1 Buparlisib triple-receptor negative breast cancer no benefit detail...
MET over exp Buparlisib + Crizotinib triple-receptor negative breast cancer unknown detail...
Unknown unknown Triptolide triple-receptor negative breast cancer not applicable detail...
Unknown unknown Selumetinib + SHP099 triple-receptor negative breast cancer not applicable detail...
STK11 F354L Everolimus + Exemestane triple-receptor negative breast cancer predicted - sensitive detail...
Unknown unknown AVID200 triple-receptor negative breast cancer not applicable detail...
BRCA2 S1970* Dinaciclib + Veliparib triple-receptor negative breast cancer predicted - sensitive detail...
BRCA1 E23Vfs*17 Dinaciclib + Olaparib triple-receptor negative breast cancer predicted - sensitive detail...
BRCA1 R1443* Dinaciclib + Veliparib triple-receptor negative breast cancer predicted - sensitive detail...
Unknown unknown LTX-315 + Pegylated liposomal-doxorubicin triple-receptor negative breast cancer not applicable detail...
Unknown unknown CC-671 triple-receptor negative breast cancer not applicable detail...
Unknown unknown Capivasertib + Paclitaxel triple-receptor negative breast cancer not applicable detail...
AKT1 mutant Capivasertib + Paclitaxel triple-receptor negative breast cancer predicted - sensitive detail...
PTEN mutant Capivasertib + Paclitaxel triple-receptor negative breast cancer predicted - sensitive detail...
MET amp Crizotinib triple-receptor negative breast cancer predicted - sensitive detail...
MET amp MET D1228N Crizotinib triple-receptor negative breast cancer predicted - resistant detail...
MET amp MET D1228N Cabozantinib triple-receptor negative breast cancer predicted - sensitive detail...
Unknown unknown MIW815 + Spartalizumab triple-receptor negative breast cancer not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00576654 Phase I Irinotecan Veliparib Irinotecan Hydrochloride and Veliparib in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery Active, not recruiting
NCT00740805 Phase I Aldoxorubicin + Cyclophosphamide + Veliparib Veliparib, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Non-Hodgkin Lymphoma Active, not recruiting
NCT01116648 Phase Ib/II Olaparib Cediranib + Olaparib Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer Active, not recruiting
NCT01351103 Phase I LGK974 LGK974 + Spartalizumab A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands Recruiting
NCT01391143 Phase I MGA271 Safety Study of MGA271 in Refractory Cancer Active, not recruiting
NCT01587703 Phase I GSK525762 A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers Active, not recruiting
NCT01623349 Phase I Alpelisib + Olaparib Buparlisib + Olaparib Phase I Study of the Oral PI3kinase Inhibitor BKM120 or BYL719 and the Oral PARP Inhibitor Olaparib in Patients With Recurrent Triple Negative Breast Cancer or High Grade Serous Ovarian Cancer Active, not recruiting
NCT01639248 ENMD-2076 A Phase II Study of the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Previously Treated Locally Advanced and Metastatic Triple-Negative Breast Cancer Completed
NCT01653470 Phase I Carboplatin Fluorouracil + Irinotecan + Leucovorin BMS-906024 Paclitaxel Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors Completed
NCT01695005 Phase I LY3039478 A Study of LY3039478 in Participants With Advanced Cancer Completed
NCT01876251 Docetaxel + PF-03084014 A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer Terminated
NCT01884285 Phase I AZD8186 Abiraterone + AZD8186 AZD8186 + Vistusertib AZD8186 First Time In Patient Ascending Dose Study Recruiting
NCT01920061 Phase I Dacomitinib + Gedatolisib Cisplatin + Gedatolisib Docetaxel + Gedatolisib A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC) Recruiting
NCT01928394 Phase Ib/II Ipilimumab + Nivolumab Cobimetinib + Ipilimumab + Nivolumab Nivolumab Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors Active, not recruiting
NCT01931163 Phase II Everolimus NECTAR Everolimus Plus Cisplatin in Triple (-) Breast Cancer Completed
NCT01938638 Phase I BAY1143572 Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer Completed
NCT01969643 Phase I SGN-LIV1A SGN-LIV1A + Trastuzumab A Safety Study of SGN-LIV1A in Breast Cancer Patients Recruiting
NCT01982448 Phase II Paclitaxel Cisplatin Cisplatin vs Paclitaxel for Triple Neg Active, not recruiting
NCT01990209 Phase II Orteronel Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR) Recruiting
NCT01997333 Phase II Glembatumumab vedotin Capecitabine Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer Completed
NCT01999738 Phase I EC1456 Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors Completed
NCT02000882 Phase II Buparlisib + Capecitabine Capecitabine + BKM120 TNBC BC Brain Met Active, not recruiting
NCT02003092 Phase I RX-5902 RX-5902 Treatment of Subjects With Solid Tumors Active, not recruiting
NCT02014337 Phase I Eribulin + Mifepristone Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors Completed
NCT02071862 Phase I CB-839 + Everolimus CB-839 + Erlotinib CB-839 + Docetaxel CB-839 CB-839 + Paclitaxel Cabozantinib + CB-839 Study of the Glutaminase Inhibitor CB-839 in Solid Tumors Active, not recruiting
NCT02078752 Phase I PF-06647263 A Study Of PF-06647263 In Patients With Advanced Solid Tumors Terminated
NCT02101385 Phase II Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer Active, not recruiting
NCT02120469 Phase I Eribulin + Everolimus Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer Active, not recruiting
NCT02138812 Phase I BAY1161909 + Paclitaxel Phase I Dose Escalation of Oral BAY1161909 in Combination With Intravenous Paclitaxel Terminated
NCT02157792 Phase I Irinotecan + VX-970 Cisplatin + Gemcitabine + VX-970 Cisplatin + Etoposide + VX-970 Cisplatin + VX-970 Carboplatin + Cisplatin + VX-970 Gemcitabine + VX-970 M6620 First in Human Study Active, not recruiting
NCT02158507 Phase I Lapatinib + Veliparib Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer Active, not recruiting
NCT02162719 Phase II Ipatasertib + Paclitaxel Paclitaxel A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Front-line Treatment for Patients With Metastatic Triple-Negative Breast Cancer Active, not recruiting
NCT02178722 Phase Ib/II Epacadostat + Pembrolizumab A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Pembrolizumab (MK-3475) in Combination With Epacadostat (INCB024360) in Subjects With Selected Cancers (INCB 24360-202 / MK-3475-037 / KEYNOTE-037/ ECHO-202) Active, not recruiting
NCT02187991 Phase II Paclitaxel Alisertib + Paclitaxel Study to Compare Alisertib With Paclitaxel vs. Paclitaxel Alone in Metastatic or Locally Recurrent Breast Cancer Active, not recruiting
NCT02203513 Phase II Prexasertib A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer Recruiting
NCT02208375 Phase Ib/II Capivasertib + Olaparib Olaparib + Vistusertib A Phase Ib Study of the Oral PARP Inhibitor Olaparib With the Oral mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial, Triple Negative Breast, and Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Active, not recruiting
NCT02222922 Phase I Avelumab + PF-06647020 Fluconazole PF-06647020 A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors Active, not recruiting
NCT02281409 Phase Ib/II Mogamulizumab Safety, Tolerability, and Immunoregulatory Activity of Mogamulizumab (KW-0761) in Subjects With Advanced and/or Metastatic Solid Tumors Recruiting
NCT02299635 Phase II PF-03084014 A Study Evaluating PF-03084014 In Patients With Advanced Breast Cancer With Or Without Notch Alterations Terminated
NCT02307240 Phase I CUDC-907 Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors Active, not recruiting
NCT02358200 Phase I Carboplatin + Paclitaxel + Talazoparib Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer Active, not recruiting
NCT02365662 Phase I ABBV-221 A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor Terminated
NCT02366949 Phase I BAY1217389 + Paclitaxel Paclitaxel Phase I Study of Oral BAY 1217389 in Combination With Intravenous Paclitaxel Completed
NCT02368691 Phase II enobosarm Efficacy and Safety of GTx-024 in Patients With Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC) Terminated
NCT02370238 Phase II Reparixin A Double-blind Study of Paclitaxel in Combination With Reparixin or Placebo for Metastatic Triple-Negative Breast Cancer Active, not recruiting
NCT02375958 Phase I PCA062 PCA062 in pCAD-positive Tumors. Completed
NCT02393794 Phase Ib/II Cisplatin + Nivolumab + Romidepsin Cisplatin + Romidepsin Romidepsin Plus Cisplatin in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) Recruiting
NCT02401347 Phase II Talazoparib Phase II Talazoparib in BRCA1 +BRCA2 Wild-Type &Triple-Neg /HER2-Negative Breast Cancer /SolidTumors Recruiting
NCT02419417 Phase Ib/II BMS986158 Paclitaxel Study of BMS-986158 in Subjects With Select Advanced Solid Tumors Recruiting
NCT02425891 Phase III Nab-paclitaxel Atezolizumab A Study of MPDL3280A in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel for Patients With Previously Untreated Metastatic Triple Negative Breast Cancer Active, not recruiting
NCT02427581 Phase I Poly ICLC Safety and Immunogenicity of a Personalized Synthetic Long Peptide Breast Cancer Vaccine Strategy in Patients With Persistent Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy Recruiting
NCT02432963 Phase I MVAp53 + Pembrolizumab Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy Active, not recruiting
NCT02435680 Phase II MCS110 Carboplatin + Gemcitabine Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC) Active, not recruiting
NCT02447003 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) Monotherapy for Metastatic Triple-Negative Breast Cancer (MK-3475-086/KEYNOTE-086) Active, not recruiting
NCT02452424 Phase Ib/II Pembrolizumab + Pexidartinib A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors Completed
NCT02456857 Phase II Bevacizumab Doxorubicin Temsirolimus Liposomal Doxorubicin, Bevacizumab and Temsirolimus (DAT) in Triple-Negative Breast Cancer (TNBC) Insensitive to Standard Neoadjuvant Chemotherapy Recruiting
NCT02457910 Phase Ib/II Enzalutamide Enzalutamide + Taselisib Taselisib and Enzalutamide in Treating Patients With Androgen Receptor Positive Triple-Negative Metastatic Breast Cancer Active, not recruiting
NCT02471846 Phase I GDC-0919 Atezolizumab A Study of GDC-0919 and MPDL3280A Combination Treatment in Participants With Locally Advanced or Metastatic Solid Tumors Active, not recruiting
NCT02474173 Phase I Paclitaxel Onalespib HSP90 Inhibitor AT13387 and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer Recruiting
NCT02489448 Phase Ib/II Durvalumab + Nab-paclitaxel Cyclophosphamide + Doxorubicin Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer Recruiting
NCT02498613 Phase II Cediranib + Olaparib A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors Recruiting
NCT02513472 Phase Ib/II Eribulin + Pembrolizumab Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Subjects With Metastatic Triple-Negative Breast Cancer (mTNBC) Active, not recruiting
NCT02528357 Phase I GSK3174998 Pembrolizumab GSK3174998 Alone or With Pembrolizumab in Subjects With Advanced Solid Tumors Recruiting
NCT02530489 Phase II Atezolizumab + Nab-paclitaxel Neoadjuvant Trial of Nab-Paclitaxel and MPDL3280A Recruiting
NCT02531932 Phase II Carboplatin Everolimus Comparison of Single-Agent Carboplatin vs the Combination of Carboplatin and Everolimus for the Treatment of Advanced Triple-Negative Breast Cancer Recruiting
NCT02540291 Phase I E7046 Study of E7046 in Subjects With Selected Advanced Malignancies Terminated
NCT02543645 Phase Ib/II Atezolizumab + Varlilumab A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer Terminated
NCT02554812 Phase Ib/II Avelumab + PF-04518600 Avelumab + PD 0360324 Avelumab + Utomilumab Avelumab + PF-04518600 + Utomilumab A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley) Recruiting
NCT02555657 Phase III Pembrolizumab Eribulin Gemcitabine Vinorelbine Capecitabine Study of Single Agent Pembrolizumab (MK-3475) Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer (MK-3475-119/KEYNOTE-119) Active, not recruiting
NCT02559492 Phase I Epacadostat + Itacitinib Itacitinib + Parsaclisib INCB039110 Combined With INCB024360 and/or INCB039110 Combined With INCB050465 in Advanced Solid Tumors Active, not recruiting
NCT02574455 Phase III Sacituzumab govitecan Capecitabine + Eribulin + Gemcitabine + Vinorelbine Study of Sacituzumab Govitecan in Refractory/Relapsed Triple-Negative Breast Cancer Recruiting
NCT02575781 Phase I SAR428926 A Study of SAR428926 in Patients With Advanced Solid Tumors Completed
NCT02580448 Phase Ib/II VT-464 A Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of VT-464 in Patients With Advanced Breast Cancer Completed
NCT02593175 Phase II Carboplatin + Paclitaxel + Panitumumab Women's Triple-Negative First-Line Study: A Phase II Trial of Panitumumab, Carboplatin and Paclitaxel (PaCT) in Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive to Standard Neoadjuvant Chemotherapy Recruiting
NCT02624700 Phase II Pemetrexed + Sorafenib Study of Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer Active, not recruiting
NCT02627430 Phase I Onalespib + Talazoparib Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer Withdrawn
NCT02628535 Phase I MGD009 Safety Study of MGD009 in B7-H3-expressing Tumors Recruiting
NCT02631733 Phase I Irinotecan + Veliparib Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery Suspended
NCT02632448 Phase Ib/II Gemcitabine + LY2880070 LY2880070 A Study of LY2880070 in Participants With Advanced or Metastatic Cancer Recruiting
NCT02637375 Phase I Cyclophosphamide + Doxorubicin + Paclitaxel Ganetespib A Pilot Preoperative Trial of Ganetespib With Paclitaxel for Triple-Negative Breast Cancer Withdrawn
NCT02644369 Phase II Pembrolizumab Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors (INSPIRE) Active, not recruiting
NCT02646748 Phase I Itacitinib + Pembrolizumab Parsaclisib + Pembrolizumab Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors Active, not recruiting
NCT02648477 Phase II Letrozole + Pembrolizumab Exemestane + Pembrolizumab Anastrozole + Pembrolizumab Doxorubicin + Pembrolizumab Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer Recruiting
NCT02655822 Phase I Atezolizumab + CPI-444 CPI-444 Phase 1/1b Study to Evaluate the Safety and Tolerability of CPI-444 Alone and in Combination With Atezolizumab in Advanced Cancers Recruiting
NCT02657889 Phase Ib/II Niraparib + Pembrolizumab Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer (TOPACIO) Active, not recruiting
NCT02658214 Phase I Cisplatin + Durvalumab + Fluorouracil + Tremelimumab Durvalumab + Gemcitabine + Nab-paclitaxel + Tremelimumab Durvalumab + Fluorouracil + Leucovorin + Oxaliplatin + Tremelimumab Carboplatin + Durvalumab + Nab-paclitaxel + Tremelimumab Carboplatin + Durvalumab + Etoposide + Tremelimumab Carboplatin + Durvalumab + Paclitaxel + Tremelimumab Carboplatin + Durvalumab + Gemcitabine + Tremelimumab Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors Active, not recruiting
NCT02660034 Phase I BGB-A317 + Pamiparib The Safety, Pharmacokinetics and Antitumor Activity of BGB-A317 in Combination With BGB-290 in Subjects With Advanced Solid Tumors Recruiting
NCT02672475 Phase I Galunisertib + Paclitaxel Galunisertib and Paclitaxel in Treating Patients With Metastatic Androgen Receptor Negative (AR-) Triple Negative Breast Cancer Recruiting
NCT02676986 Phase II Enzalutamide + Exemestane Enzalutamide Short-term Preoperative Treatment With Enzalutamide, Alone or in Combination With Exemestane in Primary Breast Cancer (ARB) Active, not recruiting
NCT02689427 Phase II Enzalutamide + Paclitaxel Phase IIB Neoadjuvant Enzalutamide (ZT) Plus Taxol for Androgen Receptor (AR)-Positive Triple-Negative Breast Cancer (AR+ TNBC) Recruiting
NCT02698176 Phase I Birabresib A Dose Exploration Study With MK-8628 in Participants With Selected Advanced Solid Tumors (MK-8628-006) Terminated
NCT02708680 Phase Ib/II Atezolizumab Atezolizumab + Entinostat Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In Active, not recruiting
NCT02719691 Phase I Alisertib + Sapanisertib Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer Recruiting
NCT02720185 Phase II Dasatinib The Window of Opportunity of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR Suspended
NCT02725489 Phase II Durvalumab + FANG vaccine Pilot Study of Durvalumab (MEDI4736) in Combination With Vigil in Advanced Breast Cancer Enrolling by invitation
NCT02730130 Phase II Pembrolizumab Study to Assess the Efficacy of Pembrolizumab Plus Radiotherapy in Metastatic Triple Negative Breast Cancer Patients Active, not recruiting
NCT02734290 Phase Ib/II Capecitabine + Pembrolizumab Paclitaxel + Pembrolizumab Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer Recruiting
NCT02750358 Phase II Enzalutamide Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer Active, not recruiting
NCT02752685 Phase II Nab-paclitaxel + Pembrolizumab Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer Recruiting
NCT02755272 Phase II Pembrolizumab Carboplatin + Gemcitabine A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer Recruiting
NCT02760797 Phase I Emactuzumab + RO7009789 A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors Completed
NCT02761694 Phase I ARQ 751 + Paclitaxel ARQ 751 ARQ 751 + Fulvestrant ARQ 751 as a Single Agent or in Combination With Other Anti-Cancer Agents, in Solid Tumors With PIK3CA / AKT / PTEN Mutations Recruiting
NCT02762981 Phase Ib/II Nab-paclitaxel + Relacorilant Study to Evaluate CORT125134 in Combination With Nab-paclitaxel in Patients With Solid Tumors Recruiting
NCT02768701 Phase II Cyclophosphamide + Pembrolizumab Study Of Single-dose Cyclophosphamide +Pembrolizumab In Patients With Metastatic Triple Negative Breast Cancer Active, not recruiting
NCT02783300 Phase I GSK3326595 Dose Escalation Study of GSK3326595 in Subjects With Solid Tumors and Non-Hodgkin's Lymphoma Recruiting
NCT02784795 Phase I Cisplatin + Gemcitabine + LY3039478 Carboplatin + Gemcitabine + LY3039478 LY3023414 + LY3039478 Abemaciclib + LY3039478 LY3039478 + Taladegib LY3039478 LY3023414 A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors Active, not recruiting
NCT02788981 Phase II Mifepristone + Nab-paclitaxel Nab-paclitaxel A Trial of Nanoparticle Albumin-Bound Paclitaxel (Nab-Paclitaxel, Abraxane) With or Without Mifepristone for Advanced, Glucocorticoid Receptor-Positive, Triple-Negative Breast Cancer Recruiting
NCT02807844 Phase Ib/II MCS110 + Spartalizumab Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies Recruiting
NCT02819518 Phase III Paclitaxel Pembrolizumab Nab-paclitaxel Carboplatin + Gemcitabine Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer (MK-3475-355/KEYNOTE-355) Active, not recruiting
NCT02824042 Phase I Anetumab ravtansine + Itraconazole Anetumab ravtansine Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole Active, not recruiting
NCT02826434 Phase I Durvalumab + Poly ICLC + PVX-410 Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer Recruiting
NCT02829723 Phase Ib/II BLZ945 BLZ945 + Spartalizumab Phase I/II Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors Recruiting
NCT02834247 Phase I Nivolumab + TAK-659 A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors Completed
NCT02834403 Phase Ib/II Pegfilgrastim Docetaxel + L-NMMA L-NMMA L-NMMA Plus Docetaxel in Refractory Locally Advanced or Metastatic Triple Negative Breast Cancer Patients Recruiting
NCT02876107 Phase II Cyclophosphamide + Doxorubicin Carboplatin + Paclitaxel + Panitumumab Carboplatin + Paclitaxel A Phase II Study of Using Panitumumab/Carboplatin/Paclitaxel (PaCT) Followed by Anthracycline-Containing Regimen (AC) for New Triple-Negative Inflammatory Breast Cancer (TN-IBC) Recruiting
NCT02876302 Phase II Cyclophosphamide + Doxorubicin + Paclitaxel + Ruxolitinib Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer Recruiting
NCT02880371 Phase Ib/II ARRY-382 + Pembrolizumab A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors Active, not recruiting
NCT02883062 Phase II Carboplatin + Paclitaxel Atezolizumab + Carboplatin + Paclitaxel Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer Suspended
NCT02890069 Phase I LCL161 + Spartalizumab Everolimus + Spartalizumab Panobinostat + Spartalizumab A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat Recruiting
NCT02898207 Phase I Olaparib + Onalespib Olaparib and Hsp90 Inhibitor AT13387 in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple-Negative Breast Cancer Recruiting
NCT02900664 Phase I Nazartinib + Spartalizumab CJM112 + Spartalizumab Spartalizumab + Trametinib Canakinumab + Spartalizumab A Study of PDR001 in Combination With CJM112, EGF816, Ilaris (Canakinumab) or Mekinist (Trametinib) Recruiting
NCT02922764 Phase I RGX-104 Nivolumab + RGX-104 A Study of RGX-104 With or Without Nivolumab in Patients With Advanced Solid Malignancies and Lymphoma Recruiting
NCT02926690 Phase I OTS167 Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer Recruiting
NCT02929576 Phase III Paclitaxel Enzalutamide + Paclitaxel Enzalutamide Efficacy and Safety Study of Enzalutamide in Combination With Paclitaxel Chemotherapy or as Monotherapy Versus Placebo With Paclitaxel in Patients With Advanced, Diagnostic-Positive, Triple-Negative Breast Cancer (ENDEAR) Withdrawn
NCT02936102 Phase I FAZ053 FAZ053 + Spartalizumab A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies. Active, not recruiting
NCT02947165 Phase I NIS793 + Spartalizumab NIS793 Phase I/Ib Study of NIS793 in Combination With PDR001 in Patients With Advanced Malignancies. Recruiting
NCT02950064 Phase I BTP-114 A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations Active, not recruiting
NCT02952248 Phase I BI 754091 A Trial to Find and Investigate a Safe Dose of a New Substance (BI 754091) for Patients With Solid Tumours Recruiting
NCT02954874 Phase III Pembrolizumab Pembrolizumab in Treating Patients With Triple-Negative Breast Cancer Recruiting
NCT02971761 Phase II enobosarm + Pembrolizumab Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer Recruiting
NCT02977468 Phase I Pembrolizumab Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer (Pembro/IORT) Recruiting
NCT02978716 Phase II Carboplatin + Gemcitabine Carboplatin + Gemcitabine + Trilaciclib Trilaciclib (G1T28), a CDK 4/6 Inhibitor, in Combination With Gemcitabine and Carboplatin in Metastatic Triple Negative Breast Cancer (mTNBC) Active, not recruiting
NCT02981303 Phase II Pembrolizumab + PGG beta-glucan Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer Active, not recruiting
NCT02984683 Phase II SAR566658 Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer Completed
NCT02985658 Phase I Cisplatin Veliparib Vinorelbine Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer Available
NCT02996825 Phase I Mirvetuximab Soravtansine Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRa-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer Recruiting
NCT03004183 Phase II Pembrolizumab AdV-tk + Valacyclovir SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC Recruiting
NCT03012230 Phase I Pembrolizumab + Ruxolitinib Pembrolizumab and Ruxolitinib Phosphate in Treating Patients With Metastatic Stage IV Triple Negative Breast Cancer Suspended
NCT03012477 Phase II Adavosertib + Cisplatin CISPLATIN + AZD-1775 In Breast Cancer Active, not recruiting
NCT03018405 Phase I NKR-2 cells A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications (THINK) Recruiting
NCT03036488 Phase III Cyclophosphamide + Epirubicin Cyclophosphamide + Doxorubicin Pembrolizumab Carboplatin + Paclitaxel Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) Active, not recruiting
NCT03044730 Phase II Capecitabine + Pembrolizumab Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by Surgery Active, not recruiting
NCT03076372 Phase I MM-310 A Study Evaluating MM-310 in Patients With Solid Tumors Recruiting
NCT03090165 Phase Ib/II Bicalutamide + Ribociclib Ribociclib and Bicalutamide in AR+ TNBC Active, not recruiting
NCT03098550 Phase Ib/II Daratumumab + Nivolumab A Study to Test the Safety and Effectiveness of Nivolumab Combined With Daratumumab in Patients With Advanced Solid Tumors or Tumors That Have Spread Active, not recruiting
NCT03106077 Phase II Mirvetuximab Soravtansine Mirvetuximab Soravtansine in Localized Triple-Negative Breast Cancer (TNBC) Recruiting
NCT03106415 Phase Ib/II Binimetinib + Pembrolizumab Pembrolizumab and Binimetinib in Treating Patients With Locally Advanced or Metastatic Triple Negative Breast Cancer Recruiting
NCT03121352 Phase I Carboplatin + Nab-paclitaxel + Pembrolizumab Pilot Study of Carboplatin, Nab-Paclitaxel and Pembrolizumab for Metastatic Triple-Negative Breast Cancer Recruiting
NCT03125902 Phase III Paclitaxel Atezolizumab + Paclitaxel A Study of Atezolizumab and Paclitaxel Versus Placebo and Paclitaxel in Participants With Previously Untreated Locally Advanced or Metastatic Triple Negative Breast Cancer (TNBC) (IMpassion131) Recruiting
NCT03130439 Phase II Abemaciclib Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer Recruiting
NCT03134638 Phase I SY-1365 A Phase 1 Study of SY-1365 in Adult Patients With Advanced Solid Tumors Recruiting
NCT03150810 Phase Ib/II Pamiparib + Temozolomide Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Subjects With Locally Advanced or Metastatic Solid Tumors Recruiting
NCT03167619 Phase II Durvalumab + Olaparib Olaparib Phase II Multicenter Study of Durvalumab and Olaparib in Platinum tReated Advanced Triple Negative Breast Cancer (DORA) (DORA) Recruiting
NCT03184558 Phase II BGB-324 + Pembrolizumab BGB324 in Combination With Pembrolizumab in Patients With TNBC Completed
NCT03193853 Phase II Cisplatin + Nab-paclitaxel MLN1117 + Sapanisertib TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer Recruiting
NCT03197935 Phase III Pegfilgrastim Doxorubicin Atezolizumab Filgrastim Nab-paclitaxel Cyclophosphamide A Study to Investigate Atezolizumab and Chemotherapy Compared With Placebo and Chemotherapy in the Neoadjuvant Setting in Participants With Early Stage Triple Negative Breast Cancer (IMpassion031) Recruiting
NCT03199040 Phase I Durvalumab Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy Recruiting
NCT03206203 Phase II Atezolizumab + Carboplatin Carboplatin Carboplatin With or Without Atezolizumab in Treating Patients With Stage IV Triple Negative Breast Cancer Recruiting
NCT03207867 Phase II PBF-509 + Spartalizumab A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma Recruiting
NCT03213041 Phase II Carboplatin + Pembrolizumab Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer Recruiting
NCT03221400 Phase Ib/II STA-8666 PEN-866 in Patients With Advanced Solid Malignancies Recruiting
NCT03225547 Phase II Mifepristone + Pembrolizumab Study of Pembrolizumab and Mifepristone in Patients With Advanced HER2-negative Breast Cancer Recruiting
NCT03243331 Phase I Gedatolisib + PF-06647020 An Initial Safety Study of Gedatolisib Plus PTK7-ADC for Metastatic Triple-negative Breast Cancer Recruiting
NCT03256344 Phase I Atezolizumab + Talimogene laherparepvec A Safety Study of Talimogene Laherparepvec Combined With Atezolizumab for Triple Negative Breast Cancer and Colorectal Cancer With Liver Metastases Recruiting
NCT03281954 Phase III Atezolizumab Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo Recruiting
NCT03289962 Phase I RO7198457 Atezolizumab + RO7198457 A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors Recruiting
NCT03292172 Phase I Atezolizumab + TEN-010 A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer Suspended
NCT03310957 Phase Ib/II Pembrolizumab + SGN-LIV1A Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer Recruiting
NCT03316586 Phase II Cabozantinib + Nivolumab A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast Cancer Recruiting
NCT03316794 Phase I SC-005 A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC) Terminated
NCT03318562 Phase II Tomivosertib A PD Study of Oral eFT508 in Subjects With Advanced TNBC and HCC Terminated
NCT03330405 Phase II Avelumab + Talazoparib Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors Recruiting
NCT03330847 Phase II Adavosertib + Olaparib Olaparib AZD6738 + Olaparib To Assess Safety and Efficacy of Agents Targeting DNA Damage Repair With Olaparib Versus Olaparib Monotherapy Recruiting
NCT03337724 Phase II Ipatasertib + Paclitaxel Paclitaxel A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer (IPATunity130) Recruiting
NCT03361800 Entinostat Window of Opportunity Trial of Entinostat in Patients With Newly Diagnosed Stage I-IIIC,TNBC Recruiting
NCT03362060 Phase I Pembrolizumab + PVX-410 PVX-410 Vaccine Plus Pembrolizumab in HLA-A2+ Metastatic Triple Negative Breast Cancer Recruiting
NCT03366844 Phase I Pembrolizumab Pilot; Open Label; Breast Cancer; Preoperative Pembrolizumab + Radiation Recruiting
NCT03371017 Phase III Atezolizumab + Capecitabine + Carboplatin + Gemcitabine Capecitabine + Carboplatin + Gemcitabine A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer (IMpassion132) Recruiting
NCT03387085 Phase Ib/II ETBX-051 Aldoxorubicin ETBX-061 Cisplatin Cyclophosphamide GI-4000 Bevacizumab ALT-803 Fluorouracil ETBX-011 Oxaliplatin Capecitabine Leucovorin GI-6301 Nab-paclitaxel Avelumab GI-6207 QUILT-3.067: Molecularly Informed Integrated Immunotherapy Combining Innate High-affinity Natural Killer (haNK) Cell Therapy With Adenoviral and Yeast-based Vaccines to Induce T-cell Responses in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy. Active, not recruiting
NCT03414684 Phase II Carboplatin + Nivolumab Carboplatin Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer Recruiting
NCT03424005 Phase Ib/II Atezolizumab + Bevacizumab Atezolizumab + Carboplatin + Gemcitabine Atezolizumab Atezolizumab + Bevacizumab + Cobimetinib Atezolizumab + Capecitabine Atezolizumab + Ipatasertib Atezolizumab + SGN-LIV1A A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Triple-Negative Breast Cancer (Morpheus-TNBC) (Morpheus-TNBC) Recruiting
NCT03435640 Phase Ib/II NKTR-214 + NKTR-262 Nivolumab + NKTR-214 + NKTR-262 A Study of NKTR-262 in Combination With NKTR-214 and With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies Recruiting
NCT03454451 Phase I CPI-006 CPI-006 + Pembrolizumab CPI-006 + CPI-444 CPI-006 Alone and in Combination With CPI-444 and With Pembrolizumab for Patients With Advanced Cancers Recruiting
NCT03483012 Phase II Atezolizumab Atezolizumab + Stereotactic Radiosurgery in Triple-negative Breast Cancer and Brain Metastasis Recruiting
NCT03487666 Phase II Capecitabine + Nivolumab Capecitabine Nivolumab OXEL: Pilot Study of Immune Checkpoint or Capecitabine or Combination Therapy as Adjuvant Therapy for TNBC With Residual Disease Recruiting
NCT03498716 Phase III Atezolizumab + Cyclophosphamide + Epirubicin + Paclitaxel Cyclophosphamide + Epirubicin + Paclitaxel A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer (IMpassion030) Recruiting
NCT03499353 Phase II Talazoparib Talazoparib For Neoadjuvant Treatment Of Germline Brca1/2 Mutation Patients With Early Triple-negative Breast Cancer Recruiting
NCT03499899 Phase II Carboplatin + LAG525 Carboplatin + LAG525 + Spartalizumab LAG525 + Spartalizumab A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer Recruiting
NCT03504488 Phase Ib/II BA3021 CAB-ROR2-ADC Safety and Efficacy Study in Patients With Solid Tumors Recruiting
NCT03517488 Phase I XmAb20717 A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) Recruiting
NCT03519178 Phase II PF-06873600 A Safety, Pharmacokinetic, Pharmacodynamic and Anti-Tumor Study of PF-06873600 as a Single Agent and in Combination With Endocrine Therapy Recruiting
NCT03538028 Phase I INCAGN02385 A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies Recruiting
NCT03542175 Phase I Rucaparib A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy Recruiting
NCT03544125 Phase I Durvalumab + Olaparib Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer Recruiting
NCT03546686 Phase II Ipilimumab + Nivolumab Peri-Operative Ipilimumab+Nivolumab and Cryoablation Versus Standard Care in Women With Triple-negative Breast Cancer Recruiting
NCT03554109 Phase II Aldoxorubicin + ALT-803 + Avelumab + Cyclophosphamide + ETBX-011 + ETBX-051 + ETBX-061 + Fluorouracil + GI-4000 + GI-6207 + GI-6301 + haNK cells + Leucovorin + Nab-paclitaxel Cyclophosphamide + Doxorubicin + Paclitaxel QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine Withdrawn
NCT03562637 Phase III Adagloxad simolenin + OBI-821 Study of Adagloxad Simolenin (OBI-822) and OBI-821 Versus Placebo Treatment for High Risk Early Stage Triple Negative Breast Cancer Patients (TNBC) Following Neoadjuvant or Adjuvant Chemotherapy. Recruiting
NCT03564782 Phase I PVSRIPO Examining Bioactivity of PVSRIPO in Triple Negative Breast Cancer Recruiting
NCT03567720 Phase II Pembrolizumab + Tavokinogene telseplasmid Intratumoral Tavo and Pembro in Patients With Inoperable Locally Advanced or Metastatic TNBC Recruiting
NCT03579472 Phase I Eribulin + M7824 M7824 and Eribulin Mesylate in Treating Participants With Metastatic Triple Negative Breast Cancer Recruiting
NCT03599453 Phase I Celecoxib + Interferon alpha-2b + Pembrolizumab + Rintatolimod Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer Recruiting
NCT03621982 Phase I Camidanlumab Tesirine Study of ADCT-301 in Patients With Selected Advanced Solid Tumors Recruiting
NCT03639948 Phase II Carboplatin + Docetaxel + Pegfilgrastim + Pembrolizumab Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast Cancer (NeoPACT) Recruiting
NCT03644589 Phase II Cisplatin + Pembrolizumab Effect of Pembrolizumab and Cisplatin on Metastatic, Locally Recurrent or Inoperable Triple-Negative Breast Cancer Withdrawn
NCT03661632 Phase Ib/II BMS-986310 + Nivolumab An Investigational Immunotherapy Study of BMS-986310 Administered Alone and in Combination With Nivolumab in Patients With Advanced Solid Tumors Recruiting
NCT03667716 Phase I COM701 COM701 + Nivolumab COM701 in Subjects With Advanced Solid Tumors Recruiting
NCT03674567 Phase Ib/II FLX475 + Pembrolizumab FLX475 Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab Recruiting
NCT03681951 Phase Ib/II GSK3145095 GSK3145095 + Pembrolizumab First-time-in-human (FTIH) Study of GSK3145095 Alone and in Combination With Other Anticancer Agents in Adults With Advanced Solid Tumors Recruiting
NCT03700294 Phase I ADCT-601 Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors Recruiting
NCT03709446 Phase Ib/II Leflunomide Leflunomide in Previously Treated Metastatic Triple Negative Cancers Recruiting
NCT03719326 Phase I AB928 + IPI-549 + Pegylated liposomal-doxorubicin AB928 + Pegylated liposomal-doxorubicin A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer and Gynecologic Malignancies Recruiting
NCT03733119 Phase II ONC201 ONC201 With and Without Methionine-Restricted Diet in Patients With Metastatic Triple Negative Breast Cancer Recruiting
NCT03742102 Phase Ib/II Durvalumab + Oleclumab + Paclitaxel Durvalumab + Paclitaxel + Selumetinib AZD9150 + Durvalumab + Paclitaxel Durvalumab + Paclitaxel Capivasertib + Durvalumab + Paclitaxel A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer. (BEGONIA) Recruiting
NCT03761914 Phase Ib/II Galinpepimut-S Galinpepimut-S + Pembrolizumab Pembrolizumab Sargramostim Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers Recruiting
NCT03775850 Phase Ib/II EDP1503 EDP1503 + Pembrolizumab A Study of EDP1503 in Patients With Colorectal Cancer, Breast Cancer, and Checkpoint Inhibitor Relapsed Tumors Recruiting
NCT03797326 Phase II Lenvatinib + Pembrolizumab Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) Recruiting
NCT03800836 Phase I Atezolizumab + Ipatasertib + Paclitaxel Atezolizumab + Ipatasertib + Nab-paclitaxel A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer Recruiting
NCT03801369 Phase II Durvalumab + Olaparib Olaparib and Durvalumab to Treat Patients With Metastatic Triple Negative Breast Cancer Recruiting
NCT03812393 Phase II Carboplatin + Neratinib + Paclitaxel Neratinib Evaluating the Efficacy of Neratinib on Live Cell HER2 Signaling Transduction Analysis Positive Triple Negative Breast (FACT-2) Not yet recruiting
NCT03821935 Phase I ABBV-151 ABBV-151 + ABBV-181 Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Subjects With Locally Advanced or Metastatic Solid Tumors Recruiting
NCT03829501 Phase Ib/II Atezolizumab + KY1044 KY1044 Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer Recruiting
NCT03849469 Phase I Pembrolizumab + XmAb22841 XmAb22841 A Study of XmAb22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4) Not yet recruiting
NCT03853707 Phase Ib/II Carboplatin + Ipatasertib + Paclitaxel Carboplatin + Ipatasertib Ipatasertib and Carboplatin With or Without Paclitaxel in Treating Patients With Metastatic Triple Negative Breast Cancer Recruiting
NCT03861403 Phase Ib/II Avelumab + Cyclophosphamide + TRX518 A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors Recruiting
NCT03872505 Phase II Carboplatin + Durvalumab + Paclitaxel Pre-operAtive Non-Anthracycline Chemotherapy, Durvalumab +/- RAdiation Therapy in Triple Negative Breast Cancer (PANDoRA) Not yet recruiting
NCT03875313 Phase Ib/II CB-839 + Talazoparib Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors Recruiting
NCT03901469 Phase II Talazoparib + ZEN003694 A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer (TNBC) Recruiting
NCT03911453 Phase I Rucaparib Window of Opportunity Trial, PARP Inhibitor Rucaparib Affect on PD-L1 Expression in Triple Negative Breast Tumors Recruiting
NCT03911973 Phase Ib/II Gedatolisib + Talazoparib Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers Not yet recruiting
NCT03945721 Phase I Niraparib A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Patients With Triple Negative Breast Cancer and an Incomplete Pathologic Response Not yet recruiting
NCT03971409 Phase II Avelumab + PF-04518600 Avelumab + Utomilumab Avelumab + Binimetinib Avelumab With Binimetinib, Utomilumab, or Anti-OX40 Antibody PF-04518600 in Treating Triple Negative Breast Cancer (InCITe) Not yet recruiting
NCT03977467 Phase II Atezolizumab + Carboplatin Atezolizumab + Cisplatin Atezolizumab Atezolizumab + Bevacizumab + Carboplatin Atezolizumab + Bevacizumab + Cisplatin Atezolizumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor Not yet recruiting
NCT03979508 Phase II Abemaciclib Abemaciclib in Treating Patients With Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer Not yet recruiting